Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study - Concepedia

Concepedia

Publication | Open Access

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

DOI Full Paper Access

111

Citations

6

References

2021

Year

Saye Khoo, Richard J. Fitzgerald, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods,

Journal of Antimicrobial Chemotherapy

Abstract

Molnupiravir was safe and well tolerated; a dose of 800 mg twice daily for 5 days was recommended for Phase II evaluation.

References

	Year	Citations

Page 1